Faktory, vliyayushchie na priverzhennost' bol'nykh k lecheniyu pri bolezni Parkinsona
- Authors: Fedorova N.V1
-
Affiliations:
- Issue: No 10 (2014)
- Pages: 41-44
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/287020
- ID: 287020
Cite item
Open Access
Access granted
Abstract
Adherence to the treatment in patients with Parkinson's disease (PD) significantly affects the control of the main symptoms of the disease, the number of decompensation, falls and motor fluctuations. Violations of the adherence to the treatment include the use of incorrect doses of drugs, taking them in the incorrect time, missing the use of drug, the abolition of drug, and the use of more than the recommended amount of the drug. One of the manifestations of poor adherence to therapy in PD is dopamine dysregulation syndrome with the development of behavioral disorders. Objective and subjective methods of assessing adherence to treatment of PD patients show contradicting results. Simplification of the regimen of use of antiparkinsonian agents, and appointment of long-acting drugs once a day are a constructive approach to the improvement of adherence to the treatment in PD patients.
Full Text
References
- World Health Organization (2003): Adherence to long-term therapies, evidence for action. Geneva: http:// www.who.int2.
- Конради А.О. Значение приверженности к терапии в лечении кардиологических заболеваний. Справочник поликлинического врача. 2007;4(6):21-5.
- Simpson S.H., Eurich D.T., Majumdar S.R., et al. Meta-analysis of the association between adherence to drug therapy and mortality. BMJ. 2006;333:15-20
- Osterberg L., Blashke T. Adherence to medication. N. Engl. J. Med. 2005;353:487-97.
- Bainbridge J.L, Ruscin L.M. Challenges of Treatment Adherence in Older Patients with Parkinson's Disease Drugs Aging. 2009;26(2): 145-55.
- Horne R. Representations of medication and treatment: advances in theory and measurement. In: Petrie K.J., Weinman J.A., editors. Perceptions of health and illness. Amsterdam: Harwood Academic, 1997. Р. 155-88.
- Левин О.С., Тумгоева А.И. Приверженность к терапии больных болезнью Паркинсона и пути ее повышения. Консилиум медикум. 2012;14(2):14-9.
- Leopold N.A., Polansky M., Hurka M.R. Drug Adherence in Parkinson's Disease. Movement Disorders. 2004;19(5):513-17.
- Grosset D. and on behalf of The European PD. Therapy Compliance Study Group. Therapy adherence issues in Parkinson's disease. J. Neurological Sciences. 2010;289:115-18.
- Valldeoriola F., Coronell C., Pon C., et al. Sociodemographic and clinical factors influencing the adherence to treatment in Parkinson's disease: the ADHESON study. European J. Neurology. 2011;18:980-87.
- Tarrants V.L., Denarie M.F., Castelli-Haley J., et al. Drug Therapies for Parkinson's Disease: A Database Analysis of Patient Compliance and Persistence. Am. J. Geriatric Pharmacother. 2010;8(4):3 74-83.
- O'Sullivan S.S., Evans A.H., Lees A.J. Dopamine Dysregulation syndrome: an overview of its epidemiology, mechanism and management. CNS Drugs. 2009;23(2):157-70.
- Giovannoni G., O'Sullivan J.D., Terner K. et al. Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J. Neurol. Neurosurg. Psych. 2000;68:423-28.
- Lawrence A.D., Evans A.H., Lees A.J. Compulsive use of dopamine replacement therapy in Parkinson's disease: reward systems gone awry? Lancet Neurol. 2003;2: 595-604.
- Evans A.H., Katzenschlager R., Pavior D., et al. Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome. Mov Disord. 2004;19:397-405.
- Morisky D.E., Green L.W., Levine D.M. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24:67-74.
- Shalansky S.J., Levy A.R., Ignaszewski A.P. Self-Reported Morisky Score for Identifying Nonadherence with Cardiovascular Medications. The Annals of Pharmacotherapy. 2004; 38:1363-68.
- Агеев Ф.Т., Фофанова Т.В., Смирнова М.Д. Методы оценки, контроля и повышения приверженности терапии. Методические рекомендации. М., 2013. 64 с.
- Grosset K.A., Bone I, Grosset D.G. Suboptimal medication adherence in Parkinson's disease. Mov. Disord. 2005;20:1502-507.
- Grosset D., Antonini A., Caneci M., et al. Adherence to antiparkinson medication in a multicenter European study. Mov. Disord. 2009;24:826-32.
- Hauser R., Salin L., Koester J. Double-blind evolution of pramipexole extended-release (ER) in early Parkinson's disease. Neurology. 2009;72( 11 Suppl. 3):412-13.
- Schapira A.H., Barone P., Hauser R.A., et al. Efficacy and safety of pramipexole extended-release for advanced Parkinson's disease. Mov. Disord. 2009;24(Suppl. 1):277-78.
Supplementary files
